In the secondary analysis, the much less conservative but clinically meaningful criterion of steady reaction (outlined to be a fifty% or more reduction in MADRS from baseline for two weeks) was used. Of the patients who realized steady reaction, 25.eight% from the esketamine group and 57.6% in the placebo group https://adolfb334zoc1.popup-blog.com/profile